Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
J&J Q2 Earnings
Description
On Wednesday, Johnson & Johnson ($JNJ@US) stated that COVID-19 vaccine sales are expected to be about $2.5 billion in their second-quarter earnings report. This is despite worries about the vaccine's safety and efficacy against the highly contagious delta variant. Johnson & Johnson outperformed analysts on the whole, and its stock was up 0.94% at press time.
More from User
00:37
Tesla FSD Clears Belgium
Benzinga
01:03
Uber Sues NYC
Benzinga
00:52
MS Limits Claude Access
Benzinga
01:14
London AI Rush
Benzinga
00:54
DJT Reaffirms Merger
Benzinga
00:56
Meta, Google Denied New Trial
Benzinga
Related Videos
01:13
Earnings Preview: Goldman Sachs (GS), Coca-Cola (KO), Johnson & Johnson (JNJ), Yahoo (YHOO), Intel (INTC)
IBTimes
03:02
COVID-19 vaccine rollout ng Johnson & Johnson sa U.S., ipinatitigil muna Alamin ang detalye mula kay PTV Correspondent @MarkFetalcoPTV Alamin ang latest na COVID-19 updates sa www.ptvnews.ph/covid-19 #Resbakuna #VacciNATION #ParaSaBayan
PTVPhilippines
02:11
Public health England: COVID-19 vaccines ng Pfizer at AstraZeneca, epektibo vs. Indian variant; Israel, tatapusin na ang pagpapatupad ng COVID-19 restrictions matapos ideklara na matagumpay ang vaccine rollout; British Prime Minister Boris Johnson, inan
PTVPhilippines
01:44
#PTVBalitaNgayon | April 24, 2021 - 1pm update PRC, nag deploy ng emergency tents sa NKTI; US-CDC at US-EDA, binary na ang rekomendasyon na itigil ang paggamit ng JNJ COVID-19 vaccine
PTVPhilippines
01:48
Samsung Electronics' Q2 earnings rose 23.48% y/y to US$ 6.8 bil. despite COVID-19
Arirang News
00:33
Pfizer's Q2 Revenue and Earnings Beat Expectations, as Sales of Pfizer's COVID Antiviral Pill Surpass Estimates
Benzinga